CN1223316A - Hemostatic fibre non-woven fabric and preparation process - Google Patents
Hemostatic fibre non-woven fabric and preparation process Download PDFInfo
- Publication number
- CN1223316A CN1223316A CN 99114610 CN99114610A CN1223316A CN 1223316 A CN1223316 A CN 1223316A CN 99114610 CN99114610 CN 99114610 CN 99114610 A CN99114610 A CN 99114610A CN 1223316 A CN1223316 A CN 1223316A
- Authority
- CN
- China
- Prior art keywords
- fibre
- hemostatic
- woven fabric
- spinning
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Artificial Filaments (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention relates to an antihaemorrhagic fibre non-woven fabric and its preparation method. It is technically characterized by that it uses polyvinyl alcohol fibre 99 and medical gelatin as main raw material, uses the extract of sweetgum leaf and berberine hydrochloride as soaking liquor, adopts improved wet spinning and afte-treatment process to obtain the semi-finished product, and then adopts the air-laid fibrous wet non-woven processing method to obtain the invented antihaemorrhagic fibre non-woven fabric series product. Said method is high in labour production efficiency, low in material consumption, excellent in antihaemorrhagic property, convenient for use, extensive in application, and can fully meet the different hemostatic requirements for various traumatic and other operations.
Description
The invention belongs to chemical fibre wet spinning and non-woven technology field.Being particularly related to a kind of is main raw material with polyvinyl alcohol (PVA) 99 and medical gelatin, serves as hemostatic fibre non-woven fabric of dipping soup and preparation method thereof with sweetgum leaf extract and berberine hydrochloride.
At present, be main raw material with PVA and gelatin, prepare the method for stanch fibre, a class is a wet spinning process, a class is the dry spinning method.Traditional wet spinning process prepares stanch fibre, is (" Chengdu engineering college journal ", 1978,1～2,60～61) of unit developments such as Inst. of Hematology, Chinese Academy of Medical Sciences, Chengdu Univ. of Science ﹠ Technology.Zhi Bei stanch fibre in this way, observe at microscope and Electronic Speculum F, the fiber section has the uneven loose core structure that is tending towards, there is not cortex closely, its inner microcellular structure that exists, make not only that specific surface increases in the fiber, and make the structure of fiber looser, therefore in use fiber present height stretch low strong, soft, permeate, adsorptivity by force, the performance characteristics rapidly of stopping blooding.But because traditional wet processing production process is long, production equipment is many, the energy, supplies consumption are big, labor productivity is low, and certain environmental pollution is arranged, so Chengdu Univ. of Science ﹠ Technology is again on the basis of wet spinning, research has been invented " medical hemostatic bibre of dry production " (CN85109219A), prepare stanch fibre with dry-spinning process, not only saved the coagulating bath system, operations such as washing, dehydration, and reduced equipment, reduce energy consumption, material consumption and production cost, improved the work working condition.Thereafter, " stanch fibre is formed and gas drawing method spining technology " (CN 1157355A) on the basis of above-mentioned technology, invented again in the Shanxi Prov. Chemical Fibre Inst.The gas drawing method spining technology that belongs to dry method has been adopted in this invention, has increased gelatin consumption in the prescription, has shortened the soak time of stanch fibre in human body; Sweetgum leaf extract and berberine hydrochloride are directly added in the spinning solution, saved the dipping operation.But purpose effect from its invention, fundamentally do not simplify existing dry-spinning process flow process, give drying but also increased fiber, formaldehyde steam normal temperature descends the operation and the equipment of stifling and balance post processing, its newly-increased process cycle reaches 13～18 hours unexpectedly, but also has increased environmental pollution.
As prior art, no matter be wet method or dry method, and the gas drawing method that belongs to dry method, all also have some problems: 1. prepared stanch fibre product all is the fiber formulation, manually mats formation, and all fails to be processed into the series of products quality homogeneous, different thickness formulations, not only make product forms, combination property can not fully satisfy the different demands of various wounds and Ge Ke surgical hemostasis, use inconvenience, range of application is limited to, and can not realize the production automation, serialization; 2. layering gradually during co-blended spinning stoste standing and defoaming causes the spinning solution instability, the spinning poor continuity, and blended fiber component heterogeneity directly influences fiber quality and serviceability; 3. oxirane poisonous, easy and air formation explosive mixture has all been adopted in the fiber sterilization, and this was both dangerous, had prolonged the stanch fibre packaging and storing cycle again (generally being no less than 9 days), and the method for sterilization after can not realizing again casing.As the remaining oxirane that trace is arranged in the fruit fiber, will produce pessimal stimulation to tissue; 4. owing in the blend stoste gelatin is arranged, its fibre-forming performance is relatively poor, causes spinning to be easy to " paste plate ", causes the repiece rate low, changes a rate height, and material loss is big.
In addition, due to the characteristics of dry technology for production itself, the stanch fibre of its preparation does not have the prepared architectural feature that the stanch fibre micropore is many, specific area is big of wet process technique on microstructure, thereby greatly inferior on hemostatic healing efficacy.
Therefore, primary and foremost purpose of the present invention is at the medical hemostatic bibre that makes full use of the wet spinning technology preparation, have on the basis of excellent hemostasis microstructure and performance, intend providing that a kind of softness, fluffy, good permeability, permeability are strong, the quality homogeneous, easy to use, help hemostatic fibre non-woven fabric series of products that further improve hemostasis comprehensive therapeutic effect and accommodation and preparation method thereof.
In view of the problems that traditional wet spinning technology exists, secondary objective of the present invention is to improve wet spinning technology, intends improving the stability of co-blended spinning stoste, the continuity of spinning and the quality of blended fiber, and reduce material consumption.
The 3rd purpose of the present invention is to improve the opener of stanch fibre, to improve the yield of stanch fibre and non-weaving cloth thereof.
The 4th purpose of the present invention provides a kind of new sterilizing methods, substitutes ethylene oxide sterilizing, to guarantee producing and drug safety minimizing environmental pollution, shortening production cycle.
The hemostatic fibre non-woven fabric that the primary order of the present invention is provided, be to be main raw material with PVA99 and medical gelatin, with sweetgum leaf extract and berberine hydrochloride is the dipping soup, after improved wet spinning process is made the semi-finished product fiber, make hemostatic fibre non-woven fabric with the non-weaving cloth processing method again, it nets heavy 30～400g/m
2, aspect intensity ratio is 1.2～1.4: 1.Wherein the solid content proportioning (weight %) of PVA99 and medical gelatin is: PVA99 32～68%; Medical gelatin 32～68%.
Its preparation method is improved wet spinning technology, comprises the preparation of co-blended spinning stoste, spinning, post processing, packing, sterilization process.
Problems at the existence of conventional wet spinning technique, the present invention at first adopts by formula rate continuous static (or dynamically) blending technology, solved the problem that layering is put in co-blended spinning stoste deaeration for a long time, soon PVA99 after difference swelling, dissolving, the deaeration and medical gelatin measure by proportioning through measuring pump and carry, direct fabrics after the continuous blend in static state (or dynamic) blender.The concentration of co-blended spinning stoste is controlled at 25～35%.Secondly on spinnerets, adopt the method that is coated with remover, solved the problem of " paste plate " in the spinning.
Simultaneously, spinning technology parameter is controlled at following scope: spray silk speed is 3～6m/min, and two sections air stretching general times are 6～9 times; Saltcake coagulating bath proportion 1.28～1.32,35 ± 2 ℃ of temperature, pH8～10, content of formaldehyde 1～3g/L; The shearing length of the fine short dimension of blend is 65 ± 5mm.
Corresponding aftertreatment technology parameter is controlled at following scope: staple fibre is handled 25～45min in the saltcake of 65～85 ℃ of proportion 1.25～1.30 temperature is bathed; The proportioning (fibre weight %) of dipping staple fibre soup is a sweetgum leaf extract 0.1～5%, berberine hydrochloride 0.1～2%, auxiliary agent I 0.05～0.5%; The bath raio of fiber impregnation soup is 1: 1.6～3.5; Behind the submersion dehydration, the air-dry temperature of fiber≤50 ℃.Wherein the auxiliary agent I is for improving the initial opener of fiber before non-woven processing, improving the stanch fibre yield and add.
Because stanch fibre intensity is low, opener is poor, in the process of non-woven processing front and back opener, fracture easily even generate short flannel, chip, the opener yield is low, generally can only reach 50～60%, in order to improve its opener, improve the fiber yield, reach the 3rd purpose of the present invention, except in dipping staple fibre soup, adding the auxiliary agent I, in the process of opener, also need spray into the auxiliary agent II simultaneously, its amount is: 0.5～5% (fibre weight %).
It is air-laid process that the present invention adopts non-woven processing method, the basic principle of air lay, be to utilize under the synergy of the centrifugal force that rotates licker-in at a high speed and air-flow, make the single fiber of peeling off dispersion cross Venturi tube with air communication, after the throat of pipe, owing to air-flow diffusion has reduced flow velocity, make originally by tactic fiber end to end to have become random random motion, on cylinder mould, be gathered into net while moving.The main feature of air lay is that fiber alignment is non-directional, and fiber becomes distributed in three dimensions, and the powerful difference of vertical, horizontal is little, and (aspect intensity ratio is 1.2～1.4: 1), demonstrate isotropic advantage.The hemostatic fibre non-woven fabric softness of being produced, fluffy, quality homogeneous, good permeability, this is for improving hemostatic healing efficacy, enlarging that to use be very favourable.Because not lapping, the output speed of lapper then is not subjected to the restriction of lapping speed, thereby output is improved greatly, and the machine floor space is also less.
The 4th purpose of the present invention is to reach by the method that adopts the gamma-radiation sterilization.
The remover that is adopted in technique scheme is an alkyl-silicone oil, can select dimethicone or diethyl silicone oil for use.The auxiliary agent I is a nonionic surface active agent, can select Span60 for use; The Span60 polyoxyethylene ether; Sorbitan monooleate; The sorbitan monooleate polyoxyethylene ether.The auxiliary agent II is an ethanol, and can select concentration for use is 70～95%.
Hemostatic fibre non-woven fabric provided by the present invention can be according to the different user demands of hemostasis, and the hemostatic fibre non-woven fabric and the hemostasis and anti-inflammation that are packaged into different size by the national drug QUALITY STANDARD paste series of products.
Compared with the prior art the present invention has the following advantages: 1. hemostatic fibre non-woven fabric provided by the present invention, not only soft, fluffy, good permeability, infiltration,
Adsorptivity is strong, the hemostatic healing efficacy height, and can directly be processed into different thickness, different size, quality homogeneous
Hemostatic fibre non-woven fabric and series of products thereof, can fully satisfy various wounds and each section's surgical hemostasis
Different demands have been widened the accommodation of stanch fibre greatly, make it to use convenient, extensive.2. the present invention has solved the layering of co-blended spinning stoste, spinning to the improvement of traditional wet spinning technology
Technology problems such as " paste plates ".Guaranteed the stability of co-blended spinning stoste, the continuity of spinning reaches
The quality of blended fiber makes the repiece rate reach 98%; Change a rate and reduced by 76%; The spinning material consumption reduces
More than 80%.3. adopt the non-woven processing method of air lay, not only output improves greatly, and the machine floor space
Little, and can be very easily with the stanch fibre of cotton shape, directly be processed into and satisfy different demands
The hemostasis series of products have fundamentally been abandoned the former craft fiber of mating formation, and the technology that the gap produces realizes
Automation, the serialization of back processing and packing, improved labor productivity.4. in stanch fibre post processing and back processing, add the opener that auxiliary agent I, II have been improved fiber respectively
The property, can make and process the yield raising thereafter more than 30%.5. adopt gamma-radiation directly to being packaged into the stanch fibre series of products sterilization of case, not only operation is very square
Just, eliminated the unsafe factor of sterilization process, avoided the remaining stimulation of oxirane, protected wound
Demonstrate,prove the security of medication, and shortened 9 days production cycles again, reduced material consumption.
Embodiment
Provide embodiment below, and the present invention is described in further detail, but technical scheme of the present invention is not limited to embodiment.
1. co-blended spinning stoste preparation
Medical gelatin and PVA99 are added soft water respectively, abundant at normal temperatures swelling, be warming up to 70～95 ℃ of stirring and dissolving, be made into 30% the aqueous solution, respectively after filtration, insulation (70～75 ℃) standing and defoaming was passed through measuring pump respectively after 3～5 hours under normal pressure, quantitatively send into the continuous blend of static mixer by 1: 1 proportioning and make spinning solution, directly send to spinning.
2. spinning
Co-blended spinning stoste is delivered to spinning head by the Spinning pumps metering, by scribbling the spinnerets of remover dimethicone, (Φ 0.08mm) extrudes through spray orifice, containing the saltcake coagulating bath (proportion 1.31 of formaldehyde (1.5g/L), 35 ± 2 ℃ of temperature, pH 8) middle solidification forming.After as-spun fibre was derived with 4m/min speed, tow was stretched to 7.5 times through the twice air, cuts into the staple fibre of 65 ± 5mm then.
3. post processing
Staple fibre humid heat treatment 40 minutes in the saltcake aqueous solution of 1.28,80 ℃ of proportions is again with the saltcake that adheres on the soft water flush away fiber, centrifugal dehydration.With the soup for preparing (containing the 30g extract in 1000ml sweetgum leaf ethanol (50%) extract, 6g berberine hydrochloride, 0.56g Span60) impregnation of fibers (bath raio 1: 1.8) 30min, air-dry under being lower than 50 ℃ then.
4. non-woven processing
With the earlier thick opener of air-dry staple fibre, spray into the ethanol (90%) of 1% (fibre weight %) simultaneously, thin again opener, after removal of impurities, mixing, the cylinder of feeding high speed rotary is further combed into filament.Under the synergy of the centrifugal force of cylinder and air-flow, fiber comes off from sawtooth, crosses Venturi tube with air communication and evenly carries, and condenses upon on the lace curtaining subsequently, and rolling into net through pressure heavily is 30～400g/m
2, the non-weaving cloth of soft, the homogeneous of quality.
5. pack
By this drug standard of country, be packaged into the hemostatic fibre non-woven fabric of certain specification or be that base material is packaged into hemostasis and anti-inflammation and pastes series of products, vanning then with the medical adhesive tape.
6. sterilization
The hemostatic fibre non-woven fabric or the hemostasis and anti-inflammation of vanning are pasted series of products,, and by this drug standard of country after the assay was approved, get product with the gamma-radiation sterilization.
Claims (10)
1. hemostatic fibre non-woven fabric, be to be main raw material with polyvinyl alcohol (PVA) 99 and medical gelatin, with sweetgum leaf extract and berberine hydrochloride is the dipping soup, it is characterized in that making the semi-finished product fiber through improved wet spinning process, use the non-weaving cloth processing method again, make hemostatic fibre non-woven fabric, it nets heavy 30～400g/m
2, aspect intensity ratio is 1.2～14: 1.
2. hemostatic fibre non-woven fabric according to claim 1, it is characterized in that PVA99 and medical gelatin solid content proportioning (weight %) are: PVA99 32～68%; Medical gelatin 32～68%.
3. method that is suitable for preparing hemostatic fibre non-woven fabric comprises: operations such as the preparation of co-blended spinning stoste, spinning, post processing, packing, sterilization, it is characterized in that after postprocessing working procedures, and adopt the non-weaving cloth processing method.
4. the preparation method of hemostatic fibre non-woven fabric according to claim 3, it is characterized in that in the spinning solution preparation section, PVA99 and medical gelatin are swelling, dissolving, filtration, deaeration respectively, through continuous static (or dynamically) blend, directly carry out spinning, the concentration of its co-blended spinning stoste is 25%～35%.
5. the preparation method of hemostatic fibre non-woven fabric according to claim 3 is characterized in that scribbling remover on the spinnerets that spinning process adopts, and spinning technique control parameter is:
1) spray silk speed is 3～6m/min, and two sections air stretching general times are 6～9 times;
2) contain formaldehyde 1～3g/L in the saltcake coagulating bath, proportion 1.28～1.32,35 ± 2 ℃ of temperature, pH8～10;
3) blend staple fibre shearing length is 65 ± 5mm.
6. the preparation method of hemostatic fibre non-woven fabric according to claim 3 is characterized in that the process control parameter of postprocessing working procedures is:
1) staple fibre humid heat treatment saltcake bath raio weighs 1.25～1.30, and 60～85 ℃ of temperature are handled 25～45min;
2) proportioning of impregnation of fibers soup (fibre weight %) is sweetgum leaf extract 0.1～5%, hydrochloric acid
Berberine 0.1～2%, auxiliary agent I 0.05～0.5%, the bath raio of fiber impregnation soup be 1: 1.2～
3.5；
3) behind the submersion dehydration, the air-dry temperature of fiber≤50 ℃.
7. the preparation method of hemostatic fibre non-woven fabric according to claim 3 is characterized in that the non-weaving cloth processing method that is adopted is an air-laid process, and sprays into the auxiliary agent II of 0.5～5% (fibre weight %) when opener.
8. according to the preparation method of claim 5 or 6 or 7 described hemostatic fibre non-woven fabrics, it is characterized in that remover is an alkyls silicone oil; The auxiliary agent I is a nonionic surface active agent; The auxiliary agent II is an ethanol.
9. the preparation method of hemostatic fibre non-woven fabric according to claim 8, it is characterized in that alkyls silicone oil can select dimethicone or diethyl silicone oil for use: nonionic surface active agent can be selected Span60, Span60 polyoxyethylene ether, sorbitan monooleate, sorbitan monooleate polyoxyethylene ether for use; It is 70%～95% that ethanol can be selected concentration for use.
10. the preparation method of hemostatic fibre non-woven fabric according to claim 3 is characterized in that sterilization process adopts the gamma-radiation sterilizing methods.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99114610A CN1116470C (en) | 1999-01-11 | 1999-01-11 | Hemostatic fibre non-woven fabric and preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99114610A CN1116470C (en) | 1999-01-11 | 1999-01-11 | Hemostatic fibre non-woven fabric and preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1223316A true CN1223316A (en) | 1999-07-21 |
| CN1116470C CN1116470C (en) | 2003-07-30 |
Family
ID=5277669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99114610A Expired - Fee Related CN1116470C (en) | 1999-01-11 | 1999-01-11 | Hemostatic fibre non-woven fabric and preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1116470C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003063922A1 (en) * | 2002-01-31 | 2003-08-07 | Aesculap Ag & Co. Kg | Haemostatic agent containing polyvinyl alcohol and provision of the same for medical use |
| CN1333126C (en) * | 2004-04-28 | 2007-08-22 | 王小建 | Method for preparing hemostatic fiber non-woven cloth |
| CN106139234A (en) * | 2015-04-24 | 2016-11-23 | 南通华尔康医疗科技股份有限公司 | A kind of manufacture method of antibacterial medical real silk stitching thread |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1157355A (en) * | 1996-10-21 | 1997-08-20 | 山西省化学纤维研究所 | Styptic fibre composition and its air-drawing process |
-
1999
- 1999-01-11 CN CN99114610A patent/CN1116470C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003063922A1 (en) * | 2002-01-31 | 2003-08-07 | Aesculap Ag & Co. Kg | Haemostatic agent containing polyvinyl alcohol and provision of the same for medical use |
| CN1333126C (en) * | 2004-04-28 | 2007-08-22 | 王小建 | Method for preparing hemostatic fiber non-woven cloth |
| CN106139234A (en) * | 2015-04-24 | 2016-11-23 | 南通华尔康医疗科技股份有限公司 | A kind of manufacture method of antibacterial medical real silk stitching thread |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1116470C (en) | 2003-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103060946B (en) | Blend fibers of alginate and sodium carboxymethyl cellulose and preparation method and application thereof | |
| CN101589853B (en) | Blumea oil microcapsule antibacterial mask and preparation method thereof | |
| CN108221081B (en) | High-strength carboxymethyl cellulose/sodium alginate blend fiber and preparation method thereof | |
| CN105200656B (en) | Nonwoven mask substrate and preparation method thereof | |
| CN107099897B (en) | A kind of viscose rayon, beautiful color fibre blending yarn and its spinning process | |
| CN107641871A (en) | Antibacterial kapok composite fibre, antibacterial filling flocculus, antibacterial kapok yarn and fabric | |
| CN107338648A (en) | A kind of preparation method of highly hygroscopic moisturizing stretch-proof silk fiber | |
| CN104005169A (en) | Polyester/polyamide composite superfine fiber high-density dust-free cloth and manufacturing method thereof | |
| CN108179546A (en) | A kind of alginate fibre non-woven fabrics and its production technology and application | |
| CN102936795A (en) | Drug-loading nano-fiber membrane and preparation method thereof | |
| CN106012092A (en) | Multifunctional protein fiber and preparation method thereof | |
| CN108914388A (en) | A kind of high-strength composite nonwoven with bacteriostasis | |
| CN1116470C (en) | Hemostatic fibre non-woven fabric and preparation process | |
| CN113183555B (en) | Breathable and dry double-layer non-woven fabric and processing technology thereof | |
| CN106400191A (en) | Composite fiber adopting skin-core type structure as well as preparation method and application of composite fiber | |
| CN111691062A (en) | Antibacterial spunlace non-woven fabric for facial soft towel | |
| CN1157355A (en) | Styptic fibre composition and its air-drawing process | |
| CN107158030A (en) | A kind of new silver-containing antibacterial product and preparation method thereof | |
| CN106521697A (en) | Carboxyethyl chitosan and polyvinyl alcohol composite fiber and preparation method and application thereof | |
| CN107338651A (en) | A kind of technique that highly hygroscopic moisturizing stretch-proof fabric is prepared using silk | |
| CN112323162B (en) | High-efficiency slow-release microcapsule cellulose fiber for wormwood | |
| CN108532058A (en) | A kind of mixed yarn spinning process of good spinnability | |
| CN108867043A (en) | A kind of preparation method and applications with the degradable carbassus of biocompatibility | |
| CN108867059A (en) | A kind of preparation method and applications of superabsorbency toughening carbassus | |
| CN108978038A (en) | A kind of preparation method of the non-woven fabric with bacteriostasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |